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The thrombomodulin (TM)/activated protein C (APC) system plays an important role in maintaining the
homeostasis of thrombosis and hemostasis and maintaining vascular integrity in vivo. TM expressed on vascular
endothelium binds to thrombin, forming a 1:1 complex and acts as an anticoagulant. In addition, the thrombin-TM
complex activates protein C to produce APC, which inactivates factors VIIIa and Va in the presence of protein S,
thereby inhibiting further thrombin formation. Intriguingly, APC possesses anti-inflammatory as well as cytoprotective
activities. Moreover, the extracellular domain of TM also possesses APC-independent anti-inflammatory and
cytoprotective activities. Of note, the TM/APC system is compromised in disseminated intravascular coagulation (DIC)
caused by sepsis due to various mechanisms, including cleavage of cell-surface TM by exaggerated cytokines and
proteases produced by activated inflammatory cells. Thus, it is reasonable to assume that reconstitution of the TM/APC
system by recombinant proteins would alleviate sepsis and DIC. On the basis of the success of the Protein C Worldwide
Evaluation in Severe Sepsis (PROWESS) trial, the FDA approved the use of recombinant human APC (rhAPC) for severe
sepsis patients in 2002. However, subsequent clinical trials failed to show clinical benefits for rhAPC, and an increased
incidence of hemorrhage-related adverse events was noted, which prompted the industry to withdraw rhAPC from
the market. On the other hand, recombinant human soluble TM (rTM) has been used for treatment of individuals
with DIC since 2008 in Japan, and a phase III clinical trial evaluating the efficacy of rTM in severe sepsis patients with
coagulopathy is now ongoing in the USA, South America, Asia, Australia, European Union, and other countries. This
review article discusses the molecular mechanisms by which the TM/APC system produces anticoagulant as well as
anti-inflammatory and cytoprotective activities in septic DIC patients.
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Disseminated intravascular coagulation (DIC) is charac-
terized by the systemic activation of coagulation caused by
various underlying diseases, with sepsis being the leading
cause [1]. The initial step of hypercoagulability caused by
sepsis is triggered by tissue factor (TF) whose expression
is induced on cell surfaces of vascular endothelial cells
and innate immune cells by pathogen-associated molecu-
lar patterns (PAMPs), such as lipopolysaccharide (LPS)
and peptidoglycan [2-5]. TF forms a complex with acti-
vated factor VII (FVIIa), which orchestrates the coagula-
tion pathway and generates thrombin [2-5]. Thrombin
converts fibrinogen to fibrin and causes fibrin deposition
in systemic microvasculature in concert with FXIIIa,Correspondence: ikezoet@kochi-u.ac.jp
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unless otherwise stated.which facilitates crosslinking of fibrin monomers [6]. In
addition to PAMPs, alarmins such as high-mobility group
box 1 protein (HMGB1) and damage-associated molecular
patterns (DAMPs), and nuclear architectural chromatin-
binding proteins including histones also activate inflam-
mation and coagulation after being liberated from necrotic/
apoptotic cells or activated by inflammatory cells [7-9].
For example, HMGB1, released into circulation, binds
to receptor for advanced glycation end products (RAGE)
on endothelial and inflammatory cells and stimulates the
production of cytokines such as interleukin-6 (IL-6) and
tumor necrosis factor α (TNFα), which further activate
systemic inflammation and hypercoagulability [10]. His-
tones, especially histones H3 and H4, stimulate the pro-
duction of inflammatory cytokines including TNFα and
IL-6 via toll-like receptors 2 and 4, which trigger activa-
tion of coagulation pathways [11]. Recent studies haves an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lar DNA fibers comprising histone and neutrophil anti-
microbial proteins released in response to microbial stimuli,
also stimulate platelets and coagulation [12-14].
In physiological conditions, the anticoagulant system
comprising antithrombin (AT), thrombomodulin (TM)/
activated protein C (APC), and tissue factor pathway in-
hibitor (TFPI) is activated in response to hypercoagulabil-
ity [3,4]. However, this anticoagulant system is severely
compromised in individuals with septic DIC by various
mechanisms; for example, levels of AT are decreased in
septic patients due to rapid clearance from circulation
after forming a complex with thrombin or its degradation
by elastases released from activated neutrophils [15]. TM
on the surfaces of vascular endothelial cells is cleaved by
neutrophil elastases. In addition, the expression of TM in
endothelium is downregulated by inflammatory cytokines
including TNFα [16]. Secondary fibrinolysis is also com-
promised in septic DIC patients, mainly because of an
increase in the expression of plasminogen activator
inhibitor-1 (PAI-1) in vascular endothelial cells that is
mediated by endotoxin and TNFα [17]. Thus, exaggerated
coagulation in parallel with impaired anticoagulant and fi-
brinolysis systems result in continuous thrombus forma-
tion in systemic small and midsize vessels, leading to organ
dysfunction, a clinical feature of septic DIC. In addition,
the exhaustion of coagulation factors and platelets results
in hemorrhage.
Recombinant human soluble TM (rTM) comprises the
extracellular domain of TM and has been used for treat-
ment of DIC since 2008 in Japan [18,19]. Post-marketing
surveillance has proven the effectiveness and safety of
this new treatment strategy to reconstitute the TM/APC
system for the management of DIC in both pediatric and
adult patients [20,21]. In addition, increasing numbers of
retrospective studies and case reports suggest that the
anti-inflammatory and cytoprotective actions of rTM are
effective in managing DIC caused by various underlying
diseases, including sepsis and fetal complications devel-
oped after hematopoietic stem cell transplantation [22-28].
rTM is now under the spotlight, and a phase III clinical
trial evaluating its efficacy in severe sepsis patients with co-
agulopathy is now ongoing in the USA, South America,
Asia, Australia, European Union, and other countries.
(https://clinicaltrials.gov/ct2/show/NCT01598831?term=ART-
123&rank=2). The use of recombinant APC was also
shown effective in reducing mortality in severely ill sepsis
patients as shown in the Protein C Worldwide Evaluation
in Severe Sepsis (PROWESS) trial and has been recom-
mended for patients with severe sepsis and DIC by the
British Committee for Standards in Haematology (BCSH)
[29,30]. However, subsequent clinical trials, including
the industry-sponsored (Eli Lilly, Indianapolis, IN, USA)
PROWESS-SHOCK trial, failed to show a benefit from theuse of rhAPC in severe sepsis patients (http://www.ema.
europa.eu/docs/en_GB/document_library/Press_release/
2011/10/WC500116970.pdf ). Given the industry's deci-
sion to withdraw rhAPC from the market, the BCSH with-
drew their recommendation of rhAPC in patients with
severe sepsis and DIC [31]. Nonetheless, accumulated re-
sults obtained from in vitro and in vivo preclinical studies
support the efficacy of APC in septic DIC, which has
attracted the attention of physicians. This review will focus
on the roles of the TM/APC system in coagulation, in-
flammation, and cytoprotection.
Review
Anticoagulant function of TM/APC
TM is a glycosylated type I transmembrane molecule of
557 amino acids with multiple domains. Each domain
possesses distinct properties. The molecule consists of
an NH2-terminal lectin-like region followed by six tan-
dem epidermal growth factor (EGF)-like structures, an
O-glycosylation site-rich domain, a transmembrane do-
main, and a cytoplasmic tail domain (Figure 1) [32]. TM
is ubiquitously expressed on endothelial cells and binds
to thrombin, forming a 1:1 complex via the fourth and
fifth (E45) repeats in an EGF-like domain and acting as an
anticoagulant [33]. In addition, the thrombin-TM complex
activates protein C (PC), a vitamin K-dependent anti-
coagulant serine protease, to produce APC [34,35]. APC is
composed of four domains: an amino-terminal gamma-
carboxyglutamic acid (Gla) domain, two epidermal growth
factor-like regions, and an enzymatic serine protease do-
main (Figure 1) [36]. APC inactivates FVIIIa and FVa by
cleavage of these coagulant factors at Arg336 and Arg562
or at Arg306 and Arg506, respectively, in the presence of
protein S, thereby inhibiting further thrombin formation
(Table 1) [37,38]. The minimum structure of TM essen-
tial to generate APC is localized in E456 repeats of the
EGF-like domain [39]. Endothelial cell protein C receptor
(EPCR) expressed on the cell surfaces of endothelium
markedly facilitates the generation of APC by binding the
Gla domain of PC and presenting it to the thrombin/TM
complex [40].
In addition to its anticoagulant activity, APC enhances
fibrinolysis by inactivation of PAI-1 (Table 1) [41]. Previ-
ous studies have shown that APC inhibits PAI-1 and pro-
motes thrombolysis in individuals with acute myocardial
infarction [42].
Anti-inflammatory and cytoprotective functions of APC
APC cleaves G protein-coupled receptor protease-activated
receptor-1 (PAR1) at Arg46 and mediates a downstream
signal transduction pathway, leading to the generation of
anti-inflammatory as well as cytoprotective activities
(Table 1) [43]. Formation of the binding complex with its

























Figure 1 Anticoagulant function of TM/APC. TM, thrombomodulin; PC, protein C; APC, activated PC; EPCR, endothelial cell protein C receptor;
PAI-1, plasminogen activator inhibitor-1; EGF, epidermal growth factor; Gla, gamma-carboxyglutamic acid.
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binding ability to APC fails to activate PAR1 [44]. Anti-
EPCR antibodies block the ability of APC to activate the
PAR1-mediated prosurvival signal transduction pathways
[45]. PAR1 requires another G protein-coupled receptor,
sphingosine 1-phosphate receptor (S1P1), to mediate the
action of APC to enhance endothelial barrier protection
(Figure 2) [46]. S1P1 activates phosphoinositide 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK),
including extracellular signal-regulated kinase (ERK),
leading to endothelial barrier protection and angiogenesis
[45,47]. The endothelial cell-specific tyrosine kinase re-
ceptor Tie2 also plays a role in APC-mediated cyto-
protection; APC increases levels of Tie2 and its ligand
angiopoietin 1 (Ang1) in concordance with the upregula-
tion of the tight junction protein zona occludens (ZO)-1
in human umbilical vein endothelial cells (HUVECs)
(Table 1, Figure 2) [48,49].
The cytoprotective function of APC is not limited to
vascular endothelial cells. APC blocks staurosporin-
mediated apoptosis of neuronal cells in association with
the inhibition of caspase 8, the nuclear translocation of
apoptosis-inducing factor, and the induction of p53. In
addition to PAR1, PAR3 is involved in APC-mediated
neuronal cell protection [50]. The cytoprotective func-
tion of APC has also been shown in an acute lung injury
(ALI) model. APC protects alveolar epithelial barrier func-
tion via EPCR/PAR1/S1P1-dependent mechanisms in con-
cert with the inhibition of the small GTPase RhoA and
the activation of Rac1, which inhibits formation ofactin-myosin stress fibers [51]. Inhaled aerosolized rhAPC
attenuates ALI in endotoxin-induced acute respiratory
distress syndrome (ARDS) and in a ventilation-induced
lung injury murine model [52,53]. Curiously, prophylactic
use of a cytoprotective-selective mutant form of APC with
reduced anticoagulant activity attenuates Pseudomonas
aeruginosa-induced ALI in a murine model and signifi-
cantly prolongs survival of these mice compared with con-
trol vehicle-treated mice (Table 1) [51,54].
Intriguingly, APC rescues mice from radiation-induced
bone marrow failure [55]. APC's mitigation of radiation tox-
icity is not merely dependent on its effect on hematopoietic
cells, as augmented TM/APC signaling in hematopoietic
progenitor cells is not able to stimulate their colony-
forming ability in vitro. A series of experiments utilizing
mutant forms of APC, including the cytoprotective-
selective 5A APC variant with reduced anticoagulant
activity and the anticoagulant-selective Glu149Ala variant
lacking anti-apoptotic activity, suggest that radiomitigation
by APC is independent of EPCR/PAR1 but is preserved in
the Glu149Ala variant [55]. The precise mechanisms by
which the APC Glu149Ala variant supports hematopoiesis
in a radiation-induced bone marrow failure murine model
remain unknown.
In addition to EPCR, APC binds to apolipoprotein E
receptor 2 (ApoER2) in U937 monocytic leukemia cells.
Upon binding to ApoE2R2, APC causes phosphorylation
of Tyr220 in adaptor protein disabled-1 (Dab1), Ser473 in
Akt, and Ser9 in glycogen synthase kinase 3β (GSK3β),
which is dependent on PI3K but not on EPCR/PAR1




Inhibits HMGB1 (alarmins) [63]
Inhibits LPS (PAMPs) [64]
Inhibits adhesion of neutrophils to
endothelial cells
[65]
Inhibits complement factors [70]
Binds to thrombin [33]
EGF-like
domain of TM
Binds to thrombin [33]
Generates APC [34,35,39]
Protects vascular endothelial cells [72]
Inhibits complement factors [68,69]
Inhibits coagulation [37,38]
Enhances fibrinolysis by inhibition of PAI-1 [41]
APC Activates G protein-coupled receptor and
protects vascular endothelial cells
[43-47],
[48,49]
Increases Tie-2 and Ang1, and protects
vascular endothelial cells
[51-54]
Mitigates acute lung injury [56]
Binds to ApoER2 and activates prosurvival
signals
[57,58]
Binds to integrin receptors and inhibits
inflammation
[59]




DIC, disseminated intravascular coagulation; TM, thrombomodulin; APC, activated
protein C; HMGB1, high-mobility group box 1; PAMPs, pathogen-associated
molecular patterns; DAMPs, damage-associated molecular patterns; PAI-1,
plasminogen activator inhibitor-1; Tie2, tyrosine kinase with Ig-like loops and
epidermal growth factor homology domains-2, Ang1, angiopoietin 1; ApoER2,
apolipoprotein E receptor 2, NF-κB, nuclear factor-κ B.
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vival signaling may contribute to the cytoprotective func-
tion of APC (Table 1, Figure 2).
Another binding partner of APC concerns the in-
tegrin family; APC binds to the heterodimeric integrin
receptor CD11b/CD18 within specialized membrane
microdomains/lipid rafts and activates PAR1/S1P1 sig-
naling, resulting in the suppression of inflammatory re-
sponses in LPS-activated macrophages (Table 1, Figure 2)
[57]. Another integrin class that elicits anti-inflammatory
functions of APC is the β1/β3-integrins. APC binds to β1/
β3-integrins and inhibits neutrophil migration in which
the Arg-Gly-Asp (RGD) sequence plays a critical role
(Table 1, Figure 2). The RGD peptide recapitulates
the beneficial effects of rhAPC on survival in an LPS-
challenged murine sepsis model [58].
The anti-inflammatory function of APC has been ele-
gantly demonstrated by microarray analyses, which have
found that APC alters the expression of various types of
genes involved in inflammation, apoptosis, and cell adhe-
sion in HUVECs. These include the anti-apoptotic Bcl-2,intracellular adhesion molecule 1, vascular cell adhesion
molecule 1, and E-selectin [59]. APC inhibits the nu-
clear factor-κ B (NF-κB), a crucial transcription factor
regulating the expression of genes involved in
inflammation and cell survival, in endothelial cells.
Modulation of NF-κB by APC at least in part plays a
role in altered gene expression mediated by APC
(Table 1) [59].
Intriguingly, APC binds to DAMPs, histone H3, and
H4 through its densely anionic N-terminal Gla domain
by means of electrostatic forces and subsequently cleaves
these histones in a PAR1-independent manner (Table 1,
Figure 2) [60,61]. Exposure of human umbilical vein EA.
hy926 cells to histones causes cell toxicity, which is
effectively blocked when these cells are cultured in
the presence of histones together with APC, suggest-
ing cytoprotective roles of APC against histones [60].
In addition, the injection of histones into mice causes
their death within 1 hour in association with a massive ac-
cumulation of neutrophils in the alveolar microvasculature,
a sign of augmented inflammation. Notably, concomitant
use of APC rescues all mice challenged with a lethal dose
of histones [60]. This anti-histone activity may be one of
the most attractive functions of APC to rescue septic DIC
patients, as significantly higher plasma levels of histone H3
are noted in non-survivors with septic DIC compared with
survivors [62].
APC-independent anti-inflammatory and cytoprotective
functions of TM
The direct anti-inflammatory function of TM is pre-
served in its lectin-like domain (Table 1). The lectin-like
domain of TM binds HMGB1 and inhibits its signaling
via RAGE (Figure 2). UV irradiation-induced inflamma-
tion, in which HMGB1 plays a role, is alleviated by
administration of the lectin-like domain of TM in as-
sociation with a decrease in leukocyte infiltration and ex-
pression of TNFα as assessed by immunohistochemistry
[63]. Of note, the use of the lectin-like domain of TM ap-
parently improves the survival of LPS-challenged mice
[63]. In vivo experiments with transgenic mice lacking the
lectin-like domain of TM (TMLeD/LeD) also provide evi-
dence for important anti-inflammatory roles of this do-
main; exposure of TMLeD/LeD mice to LPS causes shorter
survival in association with the infiltration of more poly-
morphonuclear leukocytes in organs, including lungs,
compared to wild-type counterparts (TMwt/wt mice) [64].
Further studies have found that the lectin-like domain of
TM inhibits LPS-induced cytokine production and adhe-
sion of neutrophils to endothelial cells in association with
the suppression of ERK and NF-κB [64,65]. Curiously, this
domain binds to LPS and gram-negative bacteria and in-
duces their agglutination and enhances bacterial phagocyt-
osis in macrophages [64]. Thus, the lectin-like domain of
KB
Figure 2 Anti-inflammatory and cytoprotective functions of TM/APC. HMGB1, high-mobility group box 1; PAR1, protease-activated receptor-1;
S1P1, sphingosine 1-phosphate receptor; TAFIa, active thrombin-activatable fibrinolysis inhibitor; EPCR, endothelial cell protein C receptor; ERK,
extracellular signal-regulated kinase; NF-κB, nuclear factor-κ B; Ang1, angiopoietin 1; Tie2, tyrosine kinase with Ig-like loops and epidermal
growth factor homology domains-2, ApoER2, apolipoprotein E receptor 2; Dab1, disabled-1; PAMPs, pathogen-associated molecular patterns; DAMPs,
damage-associated molecular patterns.
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mechanisms.
Other targets of TM to alleviate inflammation include
complement factors. Thrombin binds to TM efficiently
and activates thrombin-activatable fibrinolysis inhibitor
(TAFI), a procarboxypeptidase that hampers fibrinolysis
by removing C-terminal lysine residues on fibrin that are
otherwise important for the binding of plasminogen and
t-PA, thereby efficiently generating plasmin [66,67]. The
E3456 repeats of the EGF-like domain of TM are re-
quired to activate TAFI. The activated TAFI is capable of
inactivating complement C3a and C5a (Table 1) [68,69].
In addition, based on the observation that TMLeD/LeD
mice lacking the lectin-like domain of TM are more
susceptible to a mixture of monoclonal anti-collagen
type II antibody-induced arthritis, in which synovial
thickening and infiltration of inflammatory cells posi-
tive for compliment factors, including the membrane
attack complex, are featured, it has been discoveredthat the lectin-like domain of TM interferes with com-
plement activation via the classical and lectin pathways
(Table 1) [70].
Similar to APC, TM also directly binds and inactivates
histones [61,62]. Curiously, rTM inhibits extracellular
histone-induced thrombus formation in pulmonary ca-
pillaries and subsequent right-sided heart failure [62].
The negatively charged domains of TM, the O-linked
chondroitin sulfate glycosaminoglycan (GAG) moiety,
are likely to interact with cationic proteins including his-
tones. In fact, eosinophil-specific cationic protein, major
basic protein, binds to TM via the GAG moiety and
dampens its ability to generate APC, thereby promoting
fibrin clot formation [71]. However, electrostatic interac-
tions may not be the case for the binding complex for-
mation of TM and histones; the binding affinity of TM
lacking chondroitin sulfate is identical to that of TM
containing chondroitin sulfate [61]. Thus, the sites in TM
critical for binding to histones remain unknown [61,62].
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tive activity is localized in the E45 repeats of the EGF-like
domain (Table 1, Figure 2). The EGF-like domain of TM
protects calcineurin inhibitor- or IL-1β-induced apoptosis
in HUVECs in association with ERK-mediated upregula-
tion of the antiapoptotic protein Mcl-1. Importantly, this
effect is distinctive from that of APC, as single nucleotide
substitutions at codons 376 or 424 of TM, which impair
the ability of TM to produce APC or bind to thrombin,
respectively, do not hamper the cytoprotective effects
of TM [72].
Conclusions
The TM/APC system, a guardian of blood coagulation
and vascular integrity, is compromised in sepsis compli-
cated by DIC. Therapeutic strategies to reconstitute the
TM/APC system may mitigate inflammation and organ
damage associated with inhibition of thrombus formation
in septic DIC patients. These beneficial effects would
cause improvement of the survival rate of this potentially
lethal disease. The results of a phase III clinical trial of
rTM are awaited to confirm the efficacy and safety of this
agent in septic DIC patients.
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